Cabotegravir

證據等級: L5

預測適應症: 5 個

Cabotegravir: Drug Repurposing Evaluation — Insufficient Data for Full Assessment

One-Sentence Summary

Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI), approved internationally for HIV-1 treatment (in combination with rilpivirine) and HIV pre-exposure prophylaxis (PrEP). The current Evidence Pack contains no TxGNN-predicted new indications, and critical data fields — including mechanism of action, safety warnings, and contraindications — are unavailable. A complete repurposing evaluation cannot be completed until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (treatment & PrEP) — based on international approvals; not reflected in Evidence Pack
Predicted New Indication	No prediction available in this Evidence Pack
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction only; no repurposing evidence provided
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why a Full Evaluation Cannot Be Completed

The Evidence Pack for Cabotegravir (DB11751) is missing two categories of blocking data:

1. No TxGNN-predicted indications The predicted_indications array is empty. Without a candidate target disease from the model, there is no repurposing hypothesis to evaluate. It is unclear whether this reflects a model output with no high-confidence predictions, or a data pipeline gap where predictions were not retrieved.

2. Missing mechanism of action (MOA) The original_moa field is marked as a data gap. From publicly available sources, Cabotegravir is known to act as an INSTI — it blocks the HIV integrase enzyme from inserting viral DNA into the host genome. However, since this has not been confirmed through the designated data source (DrugBank API), it cannot be formally cited in this evaluation per the protocol rules.

3. No safety data Key warnings and contraindications are both listed as data gaps. Drug–drug interaction queries returned no results. Without safety information, even a preliminary safety screen (S1 assessment) cannot proceed.

Taiwan Market Information

Cabotegravir currently holds no regulatory authorizations in Taiwan. There are no licensed products, no approved dosage forms, and no approved indications on record.

Note: Internationally, Cabotegravir is marketed as Cabenuva (with rilpivirine, long-acting injectable for HIV-1 treatment) and Apretude (long-acting injectable for PrEP). These are not reflected in the Taiwanese regulatory data.

Safety Considerations

Please refer to the package insert for safety information. All safety fields in the current Evidence Pack — including key warnings, contraindications, and drug interactions — are unavailable.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack lacks the minimum required data to support any repurposing recommendation — there are no TxGNN predictions, no MOA data, and no safety information. Proceeding to evaluation without these inputs would produce unreliable conclusions.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline — confirm whether the empty predicted_indications is a true model output (no confident hits) or a retrieval failure; retrieve and load results
Retrieve MOA from DrugBank API (DB11751) — confirm integrase inhibitor mechanism and target pathways
Download and parse TFDA package insert PDF — extract key warnings and contraindications to enable S1 safety screening
Re-query DDI database — current result is not_found; verify whether this is due to drug name formatting (try "cabotegravir", "CAB", "GSK1265744") or a genuine absence of interaction data
Clarify scope — if TxGNN returns no predictions after re-run, determine whether this candidate should be retired from the repurposing pipeline or flagged for manual literature review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.